Jaguar Animal Health AI Stock Analysis
Want to see JAGX full AI Analyst Report?
Jaguar Animal Health (JAGX) AI Stock Analysis
Jaguar Animal Health
(NASDAQ:JAGX)
The overall score of 37 reflects a company in severe financial distress. The most significant factor is the combination of deep operating losses, high leverage, and consistent cash burn, which threatens the company's viability. This is compounded by a stock in freefall, trading at pennies compared to its moving averages. While recent financing maneuvers provide a temporary lifeline, they come at the substantial cost of diluting existing shareholders, offering no fundamental improvement to the company's precarious position.
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.32M
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 3.53
- Revenue Growth
- 135.52%
- EPS Growth
- 85.50%
- Country
- US
- Employees
- 47
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Jaguar Animal Health Business Overview & Revenue Model
Company Description
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are stru...
Jaguar Animal Health Earnings Call Summary
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
The company’s guidance centers on “continued business development” in 2026 with near-term clinical, regulatory and BD catalysts over the next 6–12 months and a clear goal to license its crofelemer rare-disease program: target filing of an NDA for MVID in first half of 2027 (MVID global prevalence ≈200 patients) following completion of a fully enrolled placebo‑controlled trial (with ongoing treatment‑only extension), pursuit of FDA Breakthrough designation and EMA PRIME, and parallel Phase II randomized double‑blind placebo‑controlled development in short bowel syndrome‑IF (SBS‑IF; U.S. patient estimate ≈12,000) where third‑party market estimates put opportunity at ~$8 billion; proof‑of‑concept investigator data in three pediatric IF patients showed parenteral‑support reductions of 12%–37% (12.5%–15.6% in two SBS patients, ~37% in one MVID), with even 5% reductions described as meaningful; financial guidance emphasizes non‑dilutive funding (Future Pak licensing: $18M upfront with $16M received to date, $2M conditional, ~$20M in potential milestones and >$3M additional payments reported, Future Pak also paid $3M tied to termination of a buy‑back provision), Jaguar to remain manufacturer and recognize manufacturing revenue, Q4 2025 net revenue ≈$3.2M (+5% vs Q3 2025 $3.1M; −8% vs Q4 2024 $3.5M), 2025 total net revenue ≈$11.5M (≈$11.2M from Mytesi and Canalevia‑CA1), Mytesi prescription volume down ~3.7% in 2025 vs 2024 (Q4 2025 vs Q3 2025 down ~5.8%; Q4 2025 vs Q4 2024 down ~12.2%), loss from operations increased $15.1M to $45.9M in 2025, Non‑GAAP Recurring EBITDA net loss $48.1M (2025) vs $35.9M (2024), net loss attributable to common shareholders $53.6M (2025) vs $38.5M (2024), and the company expects these clinical, regulatory and BD milestones to drive partnership discussions and additional non‑dilutive funding.
Jaguar Animal Health Financial Statement Overview
Summary
Financial health is critically weak. While gross margins are high (82.3%), the company suffers from deep operating losses (TTM net margin -132%), a highly leveraged balance sheet (debt-to-equity 3.38), and significant ongoing cash burn (TTM FCF -$6.8M). This precarious position necessitates external financing for survival.
Income Statement
35NegativeBalance Sheet
30NegativeCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.82M | 11.51M | 11.69M | 9.76M | 11.96M | 4.33M |
| Gross Profit | 22.89M | 7.74M | 9.73M | 7.72M | 9.94M | 2.00M |
| EBITDA | -39.97M | -51.73M | -36.66M | -31.53M | -33.38M | -42.37M |
| Net Income | -36.65M | -53.43M | -38.49M | -41.30M | -47.45M | -52.59M |
Balance Sheet | ||||||
| Total Assets | 34.19M | 38.32M | 53.42M | 50.76M | 47.45M | 53.27M |
| Cash, Cash Equivalents and Short-Term Investments | 6.59M | 968.00K | 8.00M | 6.47M | 5.47M | 17.05M |
| Total Debt | 16.65M | 43.61M | 36.53M | 37.09M | 34.84M | 29.36M |
| Total Liabilities | 29.27M | 57.01M | 46.93M | 45.87M | 48.81M | 41.41M |
| Stockholders Equity | 6.62M | -17.29M | 7.29M | 4.96M | -657.00K | 11.61M |
Cash Flow | ||||||
| Free Cash Flow | -6.76M | -23.71M | -29.61M | -33.24M | -34.78M | -34.98M |
| Operating Cash Flow | -6.74M | -23.69M | -29.38M | -33.24M | -33.10M | -34.97M |
| Investing Cash Flow | -41.00K | 149.00K | -231.00K | 0 | -1.68M | -6,000 |
| Financing Cash Flow | 11.30M | -44.33M | 31.20M | 34.23M | 23.18M | 43.94M |
Jaguar Animal Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 0.44 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 3.57, and below the 200-day MA of 75.34, indicating a bearish trend. The MACD of -1.06 indicates Positive momentum. The RSI at 35.80 is Neutral, neither overbought nor oversold. The STOCH value of 3.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.
Jaguar Animal Health Risk Analysis
Jaguar Animal Health disclosed 70 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksJaguar Animal Health Peers Comparison
Overall Rating
EVGN40Underperform
CODX39Underperform
GOVX38Underperform- JAGX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| EVGN | 40Underperform | $6.72M | -0.31 | 761.97% | ― | -80.59% | 59.44% |
| CODX | 39Underperform | $2.74M | -0.01 | -322.92% | ― | 28.89% | 34.53% |
| GOVX | 38Underperform | $1.36M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
| JAGX | 37Underperform | $5.83M | 0.00 | 762.51% | ― | 135.52% | 85.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JAGX | Jaguar Animal Health Inc. | 0.44 | -645.12 | -99.93% | |
| EVGN | Evogene Ltd. | 0.37 | -0.82 | -68.74% | |
| GOVX | Geovax Labs, Inc. | 2.68 | -278.72 | -99.05% | |
| CODX | Co-Diagnostics | 0.29 | -10.87 | -97.42% |
Jaguar Animal Health Corporate Events
Jaguar Health Stockholders Approve Six Proposals at Special Meeting
NeutralOn November 6, 2026, Jaguar Health stockholders approved all six proposals at a special meeting. The measures approved common-stock issuance linked to Series Q preferred stock and CVP debt, repriced investor warrants to $1 per share, expanded the 201...
Jaguar Health Announces Series R Preferred Stock Conversion
NeutralOn October 15, 2026, Jaguar Health, Inc. paid a one-time dividend of one Series R Convertible Preferred Stock share for each outstanding voting common share and each share issuable under eligible warrants, based on holders at October 13, 2026.On Nove...
Jaguar Animal Health Expands Stock Incentive Plan Proposal
NeutralOn October 8, 2026, Jaguar Health filed a definitive proxy statement ahead of a November 6, 2026 special shareholder meeting and has now supplemented it to expand Proposal 3, which seeks approval to amend and restate the 2014 Stock Incentive Plan. Th...
Jaguar Health Declares Special Series R Preferred Dividend
PositiveOn September 30, 2026, Jaguar Health amended two $12 million royalty interest agreements with Uptown Capital and Streeterville Capital, pushing the start of monthly payments from October 1, 2026 to January 1, 2027 and setting a minimum monthly royalt...
Jaguar Animal Health Executes Major Debt-for-Equity Exchange
NeutralOn September 23, 2026, Jaguar Health entered privately negotiated exchange agreements with Streeterville Capital under which it issued 182,091 common shares to reduce by $1,678,320 the outstanding balance of a secured promissory note originally issue...
Jaguar Animal Health Reduces Debt Through Equity Exchange
NeutralOn November 12, 2025, Jaguar Health, Inc. issued a secured promissory note with an original principal amount of $10.81 million to Streeterville Capital, LLC under a note purchase agreement between the parties. The note formed part of the company’s br...
Jaguar Animal Health Announces Major Equity Recapitalization
NeutralOn September 15, 2026, Jaguar Health filed a Certificate of Elimination in Delaware to remove multiple previously designated preferred stock series from its charter, returning those shares to authorized but undesignated preferred stock after all such...
Jaguar Animal Health expands ownership and restructures equity
NegativeOn September 11, 2026, Jaguar Health exchanged a 6% convertible promissory note held by Lincoln Alternative Strategies for 557,377 shares of common stock, cancelling the $175,016.36 note balance and further shifting its liabilities into equity. Betwe...
Jaguar Animal Health Announces Reverse Stock Split Plans
NeutralJaguar Health, Inc. is a biopharmaceutical company that develops novel proprietary prescription drugs sustainably derived from plants for patients with complicated gastrointestinal disease states. Through its subsidiaries Napo Pharmaceuticals and Nap...
Jaguar Health Faces Shareholder Quorum Challenge at Meeting
NegativeOn September 4, 2026, Jaguar Health convened a special meeting of stockholders but failed to secure a quorum of voting common and Series Q preferred shares, preventing any votes or business from being conducted. The company stated it will not reconve...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026